Cel therapy

Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)

01/27/2023

Global Phase 3 INDIGO study will evaluate the efficacy and safety of obexelimab in patients with IgG4-RD, a chronic and serious fibroinflammatory disease typically affecting multiple organs IgG4-RD is the first of several potential disease indications to be pursued for obexelimab given its unique non-depleting, B-cell inhibition Excerpt from the Press Release: WALTHAM, Mass., Jan.…

Read More

Stemedica Initiating Phase IIb/III Clinical Trial for Patients with Chronic Ischemic Stroke

01/25/2023

Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Stemedica Cell Technologies, a best-in-class manufacturer of ischemic tolerant, allogeneic mesenchymal stem cells (itMSC), announced today that it has initiated its “PHASE IIB/III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF A SINGLE INTRAVENOUS INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS TO SUBJECTS WITH…

Read More

ArsenalBio Announces First Patient Dosed in Phase 1 Clinical Trial of AB-1015 in Development as a Treatment for Ovarian Cancer

01/16/2023

Company will provide a business overview including product pipeline during an upcoming presentation on January 10th at the J.P. Morgan 41st Annual Healthcare Conference Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Arsenal Biosciences, Inc. (ArsenalBio), a privately held, clinical stage, programmable cell therapy company engineering advanced CAR T cell therapies for solid tumors,…

Read More

Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis

01/13/2023

As previously reported, resmetirom demonstrated improvements in NASH and liver fibrosis on liver biopsies, the primary endpoints of the MAESTRO-NASH trialA supportive analysis using consensus reads of digitized biopsy images by the central pathologists replicated the positive primary endpoint resultsThese data will be presented at the NASH-TAG Conference on Friday January 6th, 2023 Excerpt from…

Read More

Homology Medicines Provides Update on pheEDIT and juMPStart Clinical Trials and Announces Expected 2023 Milestones, Including Initial Data Read-Outs from Both Programs

01/11/2023

Strong Cash Position with Runway into Fourth Quarter 2024 Non-Clinical Data on Immunosuppression Regimen Supportive of Clinical Programs Preclinical Data from HMI-103 Gene Editing Program Utilizing a Unique Mechanism of Action Demonstrated Significantly Increased Potency in PKU Model Excerpt from the Press Release: EDFORD, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) — Homology Medicines, Inc. (Nasdaq:…

Read More

Armored CAR T Cells Break Through Immune Suppression in Solid Tumors

12/23/2022

Researchers determined the safety and antitumor ability of genetically engineered CAR T cells that circumvent immune suppression in a prostate cancer phase I clinical trial. Excerpt from the Press Release: When developing chimeric antigen receptor (CAR) T cell therapy, researchers take T cells from a patient’s blood and engineer them to target specific antigens presented…

Read More

Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company’s Second Therapeutic Candidate for Sensorineural Hearing Loss

12/20/2022

Regenerative Treatment Designed to Increase Drug Exposure Through the Cochlea; Study Results Expected in H2 2023 Frequency’s Lead Hearing Program, FX-322, on Track for Phase 2b Topline Results in Q1 2023 Excerpt from the Press Release: LEXINGTON, Mass.–(BUSINESS WIRE)–Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a…

Read More

Arcellx Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline Progress

12/12/2022

— 100% ORR at both CART-ddBCMA dose levels; deep and durable responses observed in patients with poor prognostic factors — — 27 of 38 (71%) evaluable patients reached CR/sCR; 20 of 25 patients (80%) dosed > 12 months ago or had their 12-month follow-up visit by November 22, 2022 have reached CR/sCR — — No…

Read More

Spirita Oncology, LLC Initiates a Phase 1 Clinical Trial of the Anti-Cancer Agent E6201 in Combination with Dabrafenib in Patients with Central Nervous System Metastases from BRAF V600 Mutated Metastatic Melanoma

12/08/2022

Excerpt from the Press Release: BOSTON–(BUSINESS WIRE)–Spirita Oncology, LLC, has initiated a Phase 1 clinical trial of anti-cancer agent E6201 in combination with dabrafenib in patients with BRAF V600-mutated metastatic melanoma that has spread to the central nervous system. There are approximately 47,000 new cases of metastatic melanoma in the U.S. each year, with approximately…

Read More

Electrical stimulation helps paralysed people walk again — and now we know why

11/28/2022

Detailed gene-activity map could pave way for more precise treatments for many more people with spinal-cord injuries. Excerpt from the Press Release: Neuroscientists have identified the nerve cells responsible for helping paralysed people to walk again, opening up the possibility of targeted therapies that could benefit a wider range of people with spinal-cord injuries1. Severe…

Read More